Indapta
PrivateLast Round
Early Funding
Dec 17, 2024
Total Funding Raised
$77M
Company Overview
Indapta Therapeutics is a biotechnology company specializing in the development of a proprietary off-the-shelf, non-engineered G-NK cell therapy designed to enhance immune response and improve the effectiveness of antibody treatments for cancer patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Indapta Comps
Public and private peers based on sector, stage, and business model.
Indapta Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Dec 17, 2024 | ||||
| Grant | May 15, 2024 | ||||
| Series A | Feb 10, 2022 |
Key People
Founding team and executive leadership
Indapta Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Early Funding, Series A |
| Vertex Ventures HC | Early Funding, Series A |
| Pontifax Credit | Early Funding |
| Myeloma Investment Fund | Early Funding, Series A |
| Cancer Prevention and Research Institute of Texas | Grant |
| Leaps by Bayer | Early Funding, Series A |
Indapta Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Indapta's valuation, stock price, and market status.
